INNOTEST® hPLAP

INNOTEST hPLAP (CE marked) is an enzyme immunoassay based on a unique monoclonal antibody for the quantitative determination of human placental alkaline phosphatase (hPLAP) in serum and heparinized plasma.

hPLAP (human placental alkaline phosphatase) is a marker for diagnosis and monitoring of seminomas.

    CE marked
    INNOTEST® hPLAP

    Product number 80326

    96 Tests
    Contact sales for information and inquiries
    Please contact your local Fujirebio representative for the availability of this product in your country.

    Click here to navigate

    • Details
    • Documentation
    • Product inquiry
    • Details

      Features & Benefits

      • Sample material: Serum or heparinized plasma
      • Sample volume: 2 x 100µl 
      • Standards: Ready-to-use 
      • No sample dilution
      • Contents: 12 strips with 8 wells each 

       
      Background

      hPLAP is present in the serum of pregnant women, from the second trimester onwards, produced by the placental trophoblast.

      The discovery of hPLAP by the group of W.H. Fischman in serum and tumor tissue of a male cancer patient, extensive research has indicated that in a number of types of cancer hPLAP is present in the patient's serum.

      The application of monoclonal antibodies specific for hPLAP enables measurement of this enzyme without interference from other alkaline phosphatase (AP, EC 3.1.3.1) isoenzymes.

      The hPLAP assay is an additional tool in the confirmation of diagnosis and in the monitoring of cancer patients, particularly those with seminoma, testicular, or ovarian cancer. Persistently increasing hPLAP levels can be associated with progressive malignant disease or poor response to therapy, whereas declining hPLAP levels may indicate response to treatment or of recovery.

      See:

      • Human Placental Alkaline Phosphatase (hPLAP) is the Most Frequently Elevated Serum Marker in Testicular Cancer, A. Neumann, T. Keller, D. Jocham, C. Doehn

      CAUTION: Studies indicate that smoking habits of subjects should be taken into account when evaluating serum hPLAP levels.

    • Product inquiry

      The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

      For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

      If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.